EGFR and neoplasm: In addition, the tumor cells harboring HER2YVMA mutations have been demonstrated to be resistant to reversible EGFR-TKIs such as gefitinib and erlotinib, while they remain sensitive to HER2 and dual EGFR/HER2 inhibitors [28].